effects (such as pain and time to healing), and uncertainty as to the exact lesion area to be treated. 9, 10 These issues must be taken into account by treatment guidelines to ensure maximal compliance and adherence in a largely elderly patient population and ultimately to maximise clinical efficacy in daily practice. Guidelines must also be updated to reflect current clinical practice; although recent treatments such as ingenol mebutate are included in global AK management guidelines, daylight photodynamic therapy (dl-PDT) is unclearly positioned in AK treatment guidelines. 11, 12 Table 1 presents all AK treatments with their current approved clinical indications in the European Union. A practical and up-todate consensus is necessary to further improve care in practice.
This study aimed to develop a structured consensus among clinical experts for the definition and management of AK. A systematic review of clinical guidelines for the management of AK was conducted, the output of which helped 25 Treatment of thin or nonhyperkeratotic and nonpigmented AK on the face and scalp when other therapies are considered less appropriate. Imiquimod 3.75% (Zyclara) 26 Clinically typical, nonhyperkeratotic, nonhypertrophic, visible, or palpable AK of the full face or balding scalp in immunocompetent adults when other topical treatment options are contraindicated or less appropriate. Imiquimod 5% (Aldara) 27 Clinically typical, nonhyperkeratotic, nonhypertrophic AK on the face or scalp in immunocompetent adult patients when size or number of lesions limits the efficacy and/or acceptability of cryotherapy and other topical treatment options are contraindicated or less appropriate. Ingenol mebutate (Picato) 28 Ingenol mebutate is indicated for the cutaneous treatment of nonhyperkeratotic, nonhypertrophic actinic keratosis in adults. The content of 1 tube should be used for 1 treatment area of 25 cm 2 . 5-FU + salicylic acid (Actikerall) 29 Treatment of AK. Response can be seen as early as in 6 weeks. Response increases over time and data are available for treatment up to 12 weeks. Complete healing of the lesion(s) or optimal therapeutic effect may not be evident for up to 8 weeks after treatment cessation. 5-FU (topical) (Efudix) 30 Treatment of AK. The cream should be applied thinly to the affected area once or twice daily; an occlusive dressing is not essential. Diclofenac/ hyaluronate (Solaraze) 31 Treatment of AK. The amount needed depends on the size of the lesion. Usual duration of therapy: 60 to 90 days. Maximum efficacy has been observed with treatment duration towards the upper end of this range. Complete healing of the lesion(s) or optimal therapeutic effect may not be evident for up to 30 days following cessation of therapy. Long-term efficacy not established. c-PDT ALA (Ameluz) 32 Treatment of AK of mild to moderate intensity on the face and scalp (Olsen grade 1 to 2).
AK, actinic keratosis; ALA, 5-aminolaevulinic acid; c-PDT, conventional photodynamic therapy; dl-PDT, daylight photodynamic therapy; 5-FU, 5-fluorouracil; MAL, methyl aminolevulinate.
structure a Delphi panel. A consensus meeting comprising the same participants was organised to finalise consensus statements, as illustrated in Figure 1 .
Materials and Methods
For the systematic review, databases were searched for treatment guidelines and consensus statements for the management of AK, as shown in Table 2 . Search terms for MEDLINE and EMBASE databases, respectively searched via PubMed and Ovid, are given in Appendix 1. Studies were critically assessed using the AGREE II Global Rating Scale. 13 The AGREE II assessment tool allows evaluation of guideline methodology, including guideline development methods, presentation, completeness of reporting, recommendation quality, and overall quality. The quality assessment is presented in Appendix 2. The search was conducted on September 4, 2015, and no limitations were applied in terms of publication dates; however, superseded versions of treatment guidelines were excluded.
A Delphi panel was convened to outline a structured consensus among clinical experts on the definition and management of AK on the basis of the systematic literature review.
The Delphi technique is a research method aiming to rigorously organise convergence of opinion from participants concerning real-world issues.
14 It is an iterative process whereby a questionnaire is submitted in several rounds to selected experts. Each subsequent round is supported with a non-nominative qualitative summary of the previous round. Answers from participants are computed into a paragraph without mentioning which participants supported the statements to prevent clinical experts from influencing each other. 15 Summaries were associated with a consensus level ranging from 1 to 10 (where 1 corresponded to the lowest and 10 corresponded to the highest level of consensus) to inform participants on the level of consensus achieved in the previous round.
Questions relative to treatment preferences-treatments that participants considered to be the best for patients-and demographics, for which consensus was not sought, were submitted prior to the first Delphi round. These questions together constitute what is hereafter referred to as the one-off questionnaire; participants were asked to rank treatment options they considered most suitable for the management of isolated and multiple AK from a list of 16 options. Demographic questions included aspects relative to academic and medical contributions, as well as country of practice.
The Delphi panel consisted of 3 rounds. The Delphi questionnaire was developed by a scientific committee comprising 3 expert participants on the basis of the systematic review of guidelines. It focused on issues where lack of consensus was identified (ie, AK definition/diagnosis and factors influencing AK treatment decision making). It also included a set of 3 clinical cases, represented in Figures 2 to 4 , whereby participants were required to assess the nature of AK, list their preferred management options, and express their view on the appropriateness of dl-PDT use. The latter question was included due to the absence of dl-PDT in existing guidelines, as demonstrated in the literature review.
The one-off questionnaire and Delphi panel were communicated and collected via email and included 8 and 33 questions, respectively. Sixteen clinical experts were selected on the basis of their expertise on AK and their ability to constitute a worldwide panel, represented by scientific contributions (peer-reviewed journal articles and conference keynotes) and/or clinical expertise in regards to high number of AK patients treated and/or number of AK-related clinical trials they had participated in as an investigator over the previous 5 years.
A list of treatment options for the management of AK was developed from the outputs of the Delphi panel and the systematic review of treatment guidelines. This was presented to the Delphi panel participants during a consensus meeting, and a final treatment algorithm was produced upon agreement of the expert panel.
Results

Systematic Review of Guidelines
Searches identified 612 citations for screening via database and hand searches, and 9 treatment guidelines or consensus statements published between 2007 and 2015 were ultimately extracted (Table 2) . 11, 12, [16] [17] [18] [19] [20] [21] [22] A Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram of the study flow is given in Appendix 3.
Where stated, all guidelines agreed that UV exposure was the most important causative factor for AK. Accordingly, high sun protection factor (SPF) sunscreen was recommended as a preventative measure in several guidelines. 11, 16, 18, 22 Further UV avoidance behaviours recommended by guidelines included minimising peak-time exposure to the sun (11:00 am to 3:00 pm), wearing of broadbrimmed hats outdoors, and avoidance of artificial tanning. 11, 22, 23 Within the reviewed guidelines, low consensus existed on the definition of the condition in terms of AK status as a cancer in situ or a precancerous lesion. AK was described as a premalignant or precancerous lesion in 3 guidelines. 16, 17, 22 Other guidelines regarded AK as either in situ SCC or as a form of early stage SCC. 12, [18] [19] [20] [21] Guidelines showed consensus in stating that a substantial risk exists for an AK lesion to progress to invasive SCC. Several guidelines produced guidance on grading AK severity. The Olsen grading system, or Röwbert-Huber classification, for AKs was used in some guidelines, 11, 19 while others did not report specific guidance for assessing the severity of AK. 12, 16, 17, 21, 22 A full summary of treatment recommendations across the guidelines is given in Appendix 4. For the medical and procedural management of isolated AK, the strongest recommendations made, by way of the frequency and strength of recommendation, were for cryotherapy, curettage, and conventional photodynamic therapy (c-PDT). The weakest recommendations were made for 5-fluorouracil (5-FU) and imiquimod. Recommendations relating to curettage were found to be contradictory across guidelines, with guidelines applying a strong recommendation, weak recommendation, or no stated recommendation; as such, no consensus conclusion could be made from this evidence. For the management of multiple AK lesions, the strongest recommendations were made for c-PDT and 5-FU, then imiquimod and ingenol mebutate. The weakest recommendations were made for cryotherapy and laser therapies. 8, 12, [16] [17] [18] [19] [20] [21] [22] Results associated with cryotherapy are highly dependent on the physician's experience and skills, hence the recommendation variations for cryotherapy.
Critical assessment of the extracted guidelines was performed using the AGREE II guideline evaluation tool. Three guidelines scored perfectly, 11, 12, 22 and there were no major methodological concerns for the remaining guidelines (see Appendix 2). However, reporting of strength of evidence was found to be incomplete in a minority of guidelines. 17, 20 The recent introduction of ingenol mebutate, imiquimod 3.75%, 5-FU combined with salicylic acid, and dl-PDT also rendered all guidelines obsolete, as none fully reflected the full spectrum of currently available treatments. 8 In addition, some guidelines identified in this review provided recommendations restricted to specific geographical areas. 18, 20 Some guidelines were also compromised by ignoring practicalities associated with treatment, including patient ability to comply with treatment, as well as the overall duration/ complexity of the treatment cycle. Certain guidelines imposed an overly theoretical approach to treatment, such as proposing AK maximal treatable area thresholds of 25 cm 2 , which is not a realistic threshold in clinical practice as a cheek and forehead represent 100 to 150 cm 2 and a bald scalp extends over 200 cm 2 . 17, 18 Some guidelines also advised 4-week treatment courses (eg, 5-FU, 3.75% imiquimod), 8 with likely physician follow-up visits afterwards-a prolonged treatment period that would likely prove difficult for some patients. 11, 12, [16] [17] [18] [19] [20] [21] [22] Finally, specific management for immunosuppressed patients was not addressed in some treatment guidelines.
16,22
One-Off Questionnaire and Delphi Panel
Sixteen clinical experts with extensive experience on AK participated in the Delphi panel. Over the past 5 years, participants reported a median of 75 AK patients seen on a monthly basis, 11 AK-related publications, 25 AK-related conference keynotes, and 4 AK-related clinical trials where acting as research investigator, as detailed in Table 3 .
Definition, diagnosis, and grading of AK. A consensus could not be found on the definition of AK as either cancer in situ or precancerous lesions throughout the 2 initial rounds of the Delphi panel (data not shown). A statement relative to the existence of a disease continuum from AK to invasive SCC led to a consensus. Table 4 displays consensus statements relative to the definition and diagnosis of AK. Although reservations were expressed regarding its optimality, participants agreed that the Olsen grading system was useful in clinical practice. On the clinical relevance of the number, size, and thickness of AK lesions, participants generally agreed that these were crucial criteria for evaluating the severity of AK and agreed that the distribution of AK lesions was not an important factor when establishing a diagnosis. Experts agreed that it is essential to distinguish isolated AK lesions from those occurring in small and large fields of actinic damage to make appropriate treatment decisions. Although stating that it was an arbitrary figure, participants reached the consensus that 5 AK lesions is an appropriate threshold to distinguish isolated AK (<5 lesions) from multiple AK (≥5 lesions) within a small field. Several treatments for AK are only indicated for the treatment of isolated lesions, small fields of actinic damage, and some others for large fields of actinic damage, as shown in Table 1 . The site of lesions was considered of moderate relevance for the diagnosis of AK. Participants agreed that patients with multiple AK always display a field of actinic damage surrounding the lesions.
Management of AK.
Participants agreed that decisions for the treatment of AK were based on multiple attributes-namely, patient clinical and nonclinical factors, health care, and environmental and economic factors. Table 5 and Table 6 display the consensus statements relative to these factors and attributes upon which participants agreed.
Although participants agreed that the diagnosis of AK is based on a clinical assessment, they agreed on the necessity to conduct biopsies for suspicious lesions, meaning any of (but not exclusive to) infiltrated, painful, inflamed, and/or hyperkeratotic. Efficacy of treatments was identified as a paramount factor influencing treatment decisions, regardless of the patient's immunosuppression status.
Participants also agreed that while age was not an important attribute for treatment decision making, concern was raised regarding patient capacity to comply with self-administered treatments when physical function is impaired. Achieving optimal compliance and therefore best treatment outcomes should be among the main drivers of treatment decisions, in alignment with patients' physical and mental capacity.
Similar to patient-level economic capability and technology availability, specific attributes of health care systems influence treatment decisions across the world. This is due to varying health care situations and treatment/technology availability in standard practice across different countries.
Participants agreed that the main motivation for physicians to initiate treatment for AK is the prevention of lesion progression to invasive SCC; it was considered that patients, although also concerned with cancer, have a strong preference for treating aesthetic and comfort impairments when seeking treatment for AK.
As immunosuppressed patients are at greater risk of progression to invasive SCC, a consensus was determined on the necessity for immediate primary preventive measures and curative treatments.
Resulting from the one-off questionnaire, as shown in Table 7 , the preferred management option for the treatment of isolated AK lesions was cryotherapy with an average of rank 1-although acknowledging the crucial influence of the physician's ability and experience-followed by imiquimod and the newest combination of 5-FU with salicylic acid (average rank of 4). The preferred treatment for multiple AK lesions was dl-PDT (average rank of 1). Ingenol mebutate and c-PDT were the next most preferred treatments (average rank of 2 for both).
The 3 clinical cases shown in Figures 2 to 4 represent a priori a spectrum of AK severity with varying lesion thickness (ie, respectively isolated lesions, multiple lesions in limited areas, and multiple lesions in large fields of actinic damage). Expert perception of clinical assessments, management decisions, and appropriateness of treatment options, including dl-PDT for clinical cases 1, 2, and 3, are reported in Table 8 , which presents summaries alongside the consensus level from the third round of the Delphi panel. Participants ultimately established that clinical case 1 displayed isolated AK grade I/II with uncertainty regarding field cancerisation. The participants' preferred treatment was cryotherapy, with recognised risk of hypopigmentation being a practical issue.
Consensus was found to describe clinical case 2 as multiple AK grades I, II, and III in an area of field cancerisation. Participants agreed on the need to consider biopsy for the thicker lesion and field preparation to remove hyperkeratosis Regardless of lesion thickness, there is a disease continuum extending from AK to invasive SCC.
Olsen grading: appropriate for AK diagnosis?
Although it could be improved, the Olsen grading system is appropriate mainly because it is currently a standard used in practice and in clinical trials for diagnosis and prognosis. It is a useful tool in clinical practice. Using a thin/thick grading system may also be useful. Number of lesions differentiate isolated and multiple AK
Although it is an arbitrary threshold, isolated AK is represented by fewer than 5 AK lesions, while multiple AK is represented by 5 AK lesions or more. This threshold is not fixed and other factors such as the size of the AKs and surrounding skin photo damage may modify the diagnosis. The number of lesions is of paramount importance to clinically describe the severity of AK. It is the number one criterion to assess the severity of AK. However, it is not the only criterion and needs to be combined with lesion size and thickness. Lesion size and thickness
The thickness of lesions is at least as important as the number of lesions for diagnosis. The size of lesions is a crucial criterion for the clinical definition of AK although of less importance than the number of lesions. Surrounding skin and field of actinic damage
In a patient with multiple AKs, it is very likely that surrounding skin harbours a field of actinic damage as a similar sun exposure has been sustained.
Lesion distribution
The distribution of lesions as a characteristic for the clinical assessment of AK is moderately relevant to AK diagnosis.
AK, actinic keratosis; SCC, squamous cell carcinoma. 
Topic Consensus Statement
Lesion nature Lesion number and thickness are the most important criteria (see Table 4 ). The size of lesions is also to be considered for treatment decision. Thicker and/or larger lesions may require a biopsy and prior intervention before treatment initiation and more careful follow-up. Treatment of the surrounding actinic damage may be necessary. Lesion distribution can be important when choosing treatments: hardto-reach locations for application may require the help of caregivers.
Immunosuppression status
The immunosuppression status of a patient strongly influences treatment decisions. It influences other AK characteristics such as the number and invasiveness potential of lesions. Immunosuppressed patients must be managed more carefully as they are at greater risk of invasive SCC: treatment choices are different as treatment safety and efficacy vary and knowledge is sometimes scarce in this population subgroup. Sun protection is key to prevent new lesions in immunosuppressed patients.
Patient treatment history
Patients' treatment history and their treatment preferences are important attributes for treatment decision making to ensure maximal adherence and optimal treatment outcomes. Other patient clinical attributes Several other attributes influence treatment decisions, including time to healing; patient's AK/SCC history plays a role in management decisions.
Patient characteristics
Patient's age is generally not an important attribute in treatment decisions. However, the patient's capacity to comply with treatments matters. This includes health aspects such as understanding of the treatment modality, the manual ability to manage treatments by himself or herself, and dependency or presence of family or professional caregivers. Although this can never be taken for granted, older people have a lesser focus on cosmetic aspects of the condition. This patient preference may influence treatment choices. The relevance of patients' economic status as an attribute for prescribing specific treatments varies according to countries' health care settings.
AK, actinic keratosis; SCC, squamous cell carcinoma.
before field treatment, after which c-PDT would be preferred, followed by dl-PDT or 5-FU. Here, dl-PDT was considered appropriate for the treatment of the thinner lesions.
Participants agreed that clinical case 3 displayed multiple AK lesions grades I/II and an area of field cancerisation. Field treatment would be required, with participants preferring using dl-PDT, followed by c-PDT, imiquimod, and 5-FU. Figure 5 shows the list of treatment options finalised at the consensus meeting of panel participants. Considering the number of significant factors and attributes influencing treatment decisions, including clinical data, efficacy, safety, tolerability, labels, and clinical experience, different treatment options were considered for the different clinical situations. For example, dl-PDT was rated as a preferred option for patients with multiple AKs on both small and large fields due to its efficacy and tolerability profile. Ingenol mebutate was rated as a valuable option for isolated AK lesions and multiple AK lesions on small fields due to its surface limitation per label, as well as its tolerability profile. Imiquimod 5% was rated as valuable option for the same profiles due to its tolerability profile, whereas imiquimod 3.75% was rated as valuable option for multiple AKs on a large field as per its label. This Delphi panel therefore provides an outline of treatment factors to consider when physicians assess their own clinical cases.
List of Treatment Options
On the basis of management preferences expressed by participants, a distinction was made for the management of multiple lesions and fields of actinic damage, which were further divided between small and large fields of actinic damage. Although intentionally left ill defined, as the limitation of 25 cm 2 for some approved treatments is not realistic in clinical practice, the distinction between small and large fields of actinic damage allows treatment of restricted zones (eg, nose, one cheek, or part of forehead) or entire body areas (eg, full scalp or full face). It was also decided to include In the early stages of the study, imiquimod 5% and 3.75% were not differentiated. 
Discussion
This study reports the findings of a systematic review of clinical guidelines for AK and how the results have been used, in conjunction with an evolving consensus among clinical experts, to develop both consensus statements and a treatment algorithm. The treatment algorithm accounts for recent treatments and reflects on the limitations of past guidelines. Participants agreed on a treatment algorithm for the management of isolated and multiple AKs, distinguishing lesion-directed treatment and small and large fields of actinic damage. Participants to the panel have agreed that isolated lesions should be removed with lesion-directed treatments, whereas multiple lesions should be treated differently if they spread over small or large fields. This is due to some treatments being approved only for smaller areas. Treating larger surfaces with treatments approved for smaller areas would require the physician to repeat consecutive cycles on adjacent areas, which can lead to an unacceptable overall treatment duration, increase the extent of treatment side effects, and incur a strong increase of direct and indirect costs. This study reflects current preferences of experts on management of AK and reports dl-PDT, c-PDT, ingenol mebutate, and imiquimod as preferred field treatments. This study's outcome is also supported by recent findings showing that dl-PDT has a superior tolerability profile and is more cosmetically acceptable and preferred by patients. 24 Considerations were made when detailing attributes and factors influencing treatment decision making, ranging from the patient's characteristics of AK lesions to the availability of technologies in practice.
In addition, clinical experts with extensive experience of AK management have highlighted a number of practical issues to be considered when treating AK. The consensus recommendations made are current and easily translatable to clinical practice.
The current study is a structured consensus and should not be considered a treatment guideline. This avoids the rigidity and limitations of guidelines, while providing methodologically aggregated opinions of worldwide renowned experts in the field of AK. Importantly, the consensus statement offers practical recommendations, allowing physicians to use their clinical judgement on each patient case. Furthermore, considering the limited long-term experience and knowledge on AK, a structured consensus rests among the most useful available evidence for treatment decisions at this point.
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